Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-04-27

Study Completion Date

2019-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

BCD-085 is an innovative drug, anti-interleukin-17 monoclonal antibody. The aim of the study is to evaluate the efficacy and safety of BCD-085 in patients with primary biliary cholangitis (PBC).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics

NCT06591468

Primary Biliary Cholangitis (PBC)

ENROLLING_BY_INVITATION PHASE2/PHASE3

A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05293938

Primary Biliary Cholangitis

WITHDRAWN

Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients

NCT05292872

Primary Biliary Cholangitis

COMPLETED

Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC

NCT05239468

Primary Biliary Cholangitis

COMPLETED PHASE2

Phase III Randomized Study of Ursodiol With Vs Without Methotrexate for Primary Biliary Cirrhosis

NCT00004784

Liver Cirrhosis, Biliary

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label proof-of-concept phase 2A study. The aim of the study is to evaluate the efficacy and safety of BCD-085 in combination with ursodeoxycholic acid in patients with primary biliary cholangitis (PBC) with compensated liver function with an inadequate (suboptimal) response to ursodeoxycholic acid.

In this study the inadequate (suboptimal) response to ursodeoxycholic acid (UDCA) is defined as screening alkaline phosphatase (ALP) level \> 1.67 ULN (the upper limit of normal) despite treatment with UDCA in stable dose for at least 6 months before signing the ICF.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cirrhosis, Biliary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BCD-085

All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day

Group Type EXPERIMENTAL

BCD-085

Intervention Type BIOLOGICAL

All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BCD-085

All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Singed informed consent form (ICF)
2. Men and women, age 18 - 80 years at the time of signing the ICF
3. Established diagnosis of PBC with following criteria (according to EASL 2017 guidelines):

* documented ALP elevation
* documented АМА ≥ 1:40 or PBC-specific ANА (anti-sp100/anti-gp210).
4. Suboptimal response to ursodeoxycholic acid (UDCA) taken in stable dose for at least 6 months before signing ICF with screening alkaline phosphatase (ALP) level \> 1.67 ULN (the upper limit of normal)
5. Fertile patients and their partners agree to use barrier contraception throughout the study and 4 weeks after its completion.

Exclusion Criteria

1. History of gastrointestinal bleeding, hepatic encephalopathy or ascites requiring treatment with diuretics.
2. MELD ≥ 15, history of liver transplantation, staying in the Liver Transplant Waiting List.
3. Established diagnosis of hepatocellular carcinoma (HCC), hepatorenal syndrome.
4. Direct bilirubin \> 1.0 mg/dL at screening.
5. Documented diagnosis: nonalcoholic steatohepatitis, autoimmune hepatitis, primary sclerosing cholangitis, alcoholic liver disease, Gilbert's syndrome, Wilson disease, hemochromatosis, alfa-1-antitrypsin deficiency.
6. HIV, hepatitis B, hepatitis C or syphilis.
7. Use of colchicine, methotrexate, azathioprine or systemic corticosteroids within 3 months before signing the ICF.
8. Previous use of monoclonal antibodies targeting IL17 or its receptor.
9. Vaccination with live or attenuated vaccines within 8 weeks before signing the ICF.
10. Any active systemic infection or recurrent infection at screening or 30 days before signing the ICF.
11. Established diagnosis of chronic disease (e.g. sepsis, invasive mycosis, histoplasmosis etc.) that may increase the risk of infectious adverse events during the study.
12. Severe infections (including those that required hospitalization or parenteral antibacterial/antimycotic/antiprotozoal treatment) within 6 months before signing the ICF
13. Established diagnosis of herpes zoster infection (or history of herpes zoster infection).
14. latent tuberculosis infection (positive results of the Diaskintest or QuantiFERON test, or T-spot).
15. Concurrent diseases at screening that may increase the risk of adverse events during the study or affect the evaluation of PBC symptoms (mask, enhance or alter the symptoms of PBC, or cause clinical or laboratory signs/symptoms similar to those of PBC)
16. Known allergy or intolerance to monoclonal antibody drugs (murine, chimeric, humanized, or human) or any other components of BCD-085.
17. Pregnancy, breastfeeding or planning of pregnancy during the study.
18. Any psychiatric conditions including severe depressive disorders and/or any history of suicidal thoughts or suicidal attempts that may constitute the excessive risk for the patient or that may affect the patient's ability to follow the protocol.
19. Alcohol or substance abuse.
20. Participation in other clinical trials within less than 90 days before signing the ICF.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No